Related Experiment Video

Updated: Feb 25, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced

Jon Zugazagoitia1, Daniel Rueda2, Nuria Carrizo2

  • 1Medical Oncology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación i+12, Madrid, Spain; Lung Cancer Group, Clinical Research Program, CNIO (Centro Nacional de Investigaciones Oncológicas) and Instituto de Investigación i+12, Madrid, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Clinical Lung Cancer
|August 8, 2017
PubMed
Abstract

Insights

Integrating next-generation sequencing (NGS) into lung cancer molecular subtyping is feasible. This approach identifies actionable mutations in non-small-cell lung cancer (NSCLC), guiding genotype-tailored treatments.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Non-small-cell lung cancer (NSCLC) frequently harbors targetable genetic alterations.
  • Accurate molecular subtyping is crucial for selecting appropriate therapies.

Purpose of the Study:

  • To assess the feasibility and clinical utility of incorporating a next-generation sequencing (NGS) panel into routine NSCLC molecular subtyping.
  • To evaluate the effectiveness of this integrated approach in identifying actionable mutations for targeted therapy selection.

Main Methods:

  • An amplicon-based NGS panel targeting 22 cancer gene hot spots was implemented for DNA analysis in advanced-stage NSCLCs.
  • Single-gene testing for EGFR, ALK, and ROS1 was performed alongside NGS and immunohistochemistry (IHC).
  • 109 NSCLC tumors were analyzed, with a focus on feasibility and successful sequencing rates.

Main Results:

  • Successful sequencing results were obtained in 87% of analyzed tumors.
  • Actionable mutations were identified in 37% of the entire cohort (40/109 NSCLCs).
  • KRAS (24%) and EGFR (10%) were the most common actionable mutations; 9% of patients received matched targeted therapies.

Conclusions:

  • The combination of IHC for ALK/ROS1 and amplicon-based NGS is applicable in routine clinical practice.
  • This integrated molecular profiling enables efficient patient selection for genotype-tailored treatments in NSCLC.
Keywords:
Clinical TrialsClinical next-generation sequencingGene panelsPrecision oncologyTargeted therapy

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

460
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K